236 related articles for article (PubMed ID: 32726645)
1. Hypoxia-inducible factor prolyl-hydroxylase inhibitor roxadustat (FG-4592) alleviates sepsis-induced acute lung injury.
Han F; Wu G; Han S; Li Z; Jia Y; Bai L; Li X; Wang K; Yang F; Zhang J; Wang X; Guan H; Linlin S; Han J; Hu D
Respir Physiol Neurobiol; 2020 Oct; 281():103506. PubMed ID: 32726645
[TBL] [Abstract][Full Text] [Related]
2. Hypoxia-inducible factor prolyl hydroxylase inhibitor roxadustat (FG-4592) protects against cisplatin-induced acute kidney injury.
Yang Y; Yu X; Zhang Y; Ding G; Zhu C; Huang S; Jia Z; Zhang A
Clin Sci (Lond); 2018 Apr; 132(7):825-838. PubMed ID: 29581249
[TBL] [Abstract][Full Text] [Related]
3. Hypoxia-inducible factor prolyl hydroxylase inhibitor roxadustat (FG-4592) protects against renal ischemia/reperfusion injury by inhibiting inflammation.
Miao AF; Liang JX; Yao L; Han JL; Zhou LJ
Ren Fail; 2021 Dec; 43(1):803-810. PubMed ID: 33966598
[TBL] [Abstract][Full Text] [Related]
4. Nonclinical Characterization of the Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor Roxadustat, a Novel Treatment of Anemia of Chronic Kidney Disease.
Del Balzo U; Signore PE; Walkinshaw G; Seeley TW; Brenner MC; Wang Q; Guo G; Arend MP; Flippin LA; Chow FA; Gervasi DC; Kjaergaard CH; Langsetmo I; Guenzler V; Liu DY; Klaus SJ; Lin A; Neff TB
J Pharmacol Exp Ther; 2020 Aug; 374(2):342-353. PubMed ID: 32487538
[TBL] [Abstract][Full Text] [Related]
5. Roxadustat Markedly Reduces Myocardial Ischemia Reperfusion Injury in Mice.
Deguchi H; Ikeda M; Ide T; Tadokoro T; Ikeda S; Okabe K; Ishikita A; Saku K; Matsushima S; Tsutsui H
Circ J; 2020 May; 84(6):1028-1033. PubMed ID: 32213720
[TBL] [Abstract][Full Text] [Related]
6. FG-4592 Accelerates Cutaneous Wound Healing by Epidermal Stem Cell Activation via HIF-1α Stabilization.
Tang D; Zhang J; Yan T; Wei J; Jiang X; Zhang D; Zhang Q; Jia J; Huang Y
Cell Physiol Biochem; 2018; 46(6):2460-2470. PubMed ID: 29742498
[TBL] [Abstract][Full Text] [Related]
7. Roxadustat attenuates experimental pulmonary fibrosis in vitro and in vivo.
Huang H; Wang X; Zhang X; Wang H; Jiang W
Toxicol Lett; 2020 Oct; 331():112-121. PubMed ID: 32534005
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of the Carcinogenic Potential of Roxadustat (FG-4592), a Small Molecule Inhibitor of Hypoxia-Inducible Factor Prolyl Hydroxylase in CD-1 Mice and Sprague Dawley Rats.
Beck J; Henschel C; Chou J; Lin A; Del Balzo U
Int J Toxicol; 2017; 36(6):427-439. PubMed ID: 29153032
[TBL] [Abstract][Full Text] [Related]
9. Roxadustat prevents Ang II hypertension by targeting angiotensin receptors and eNOS.
Yu J; Wang S; Shi W; Zhou W; Niu Y; Huang S; Zhang Y; Zhang A; Jia Z
JCI Insight; 2021 Sep; 6(18):. PubMed ID: 34403364
[TBL] [Abstract][Full Text] [Related]
10. Phase 2 studies of oral hypoxia-inducible factor prolyl hydroxylase inhibitor FG-4592 for treatment of anemia in China.
Chen N; Qian J; Chen J; Yu X; Mei C; Hao C; Jiang G; Lin H; Zhang X; Zuo L; He Q; Fu P; Li X; Ni D; Hemmerich S; Liu C; Szczech L; Besarab A; Neff TB; Peony Yu KH; Valone FH
Nephrol Dial Transplant; 2017 Aug; 32(8):1373-1386. PubMed ID: 28371815
[TBL] [Abstract][Full Text] [Related]
11. In Mixed Lymphocyte Reaction, the Hypoxia-Inducible Factor Prolyl-Hydroxylase Inhibitor Roxadustat Suppresses Cellular and Humoral Alloimmunity.
Eleftheriadis T; Pissas G; Mavropoulos A; Nikolaou E; Filippidis G; Liakopoulos V; Stefanidis I
Arch Immunol Ther Exp (Warsz); 2020 Oct; 68(6):31. PubMed ID: 33011826
[TBL] [Abstract][Full Text] [Related]
12. Evidence for the Capability of Roxadustat (FG-4592), an Oral HIF Prolyl-Hydroxylase Inhibitor, to Perturb Membrane Ionic Currents: An Unidentified yet Important Action.
Chang WT; Lo YC; Gao ZH; Wu SN
Int J Mol Sci; 2019 Nov; 20(23):. PubMed ID: 31795416
[TBL] [Abstract][Full Text] [Related]
13. Norisoboldine Attenuates Sepsis-Induced Acute Lung Injury by Modulating Macrophage Polarization via PKM2/HIF-1α/PGC-1α Pathway.
Chen Q; Shao X; He Y; Lu E; Zhu L; Tang W
Biol Pharm Bull; 2021; 44(10):1536-1547. PubMed ID: 34602563
[TBL] [Abstract][Full Text] [Related]
14. Stabilization of HIF-1α by FG-4592 promotes functional recovery and neural protection in experimental spinal cord injury.
Wu K; Zhou K; Wang Y; Zhou Y; Tian N; Wu Y; Chen D; Zhang D; Wang X; Xu H; Zhang X
Brain Res; 2016 Feb; 1632():19-26. PubMed ID: 26707978
[TBL] [Abstract][Full Text] [Related]
15. Propofol inhibits lipopolysaccharide-induced lung epithelial cell injury by reducing hypoxia-inducible factor-1alpha expression.
Yeh CH; Cho W; So EC; Chu CC; Lin MC; Wang JJ; Hsing CH
Br J Anaesth; 2011 Apr; 106(4):590-9. PubMed ID: 21307008
[TBL] [Abstract][Full Text] [Related]
16. Pretreatment with Roxadustat (FG-4592) Attenuates Folic Acid-Induced Kidney Injury through Antiferroptosis via Akt/GSK-3
Li X; Zou Y; Xing J; Fu YY; Wang KY; Wan PZ; Zhai XY
Oxid Med Cell Longev; 2020; 2020():6286984. PubMed ID: 32051732
[TBL] [Abstract][Full Text] [Related]
17. Oral Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor Roxadustat (FG-4592) for Treatment of Anemia in Chronic Kidney Disease: A Placebo-Controlled Study of Pharmacokinetic and Pharmacodynamic Profiles in Hemodialysis Patients.
Provenzano R; Tumlin J; Zabaneh R; Chou J; Hemmerich S; Neff TB; Yu KP
J Clin Pharmacol; 2020 Nov; 60(11):1432-1440. PubMed ID: 32603526
[TBL] [Abstract][Full Text] [Related]
18. HIF prolyl hydroxylase inhibition prior to transient focal cerebral ischaemia is neuroprotective in mice.
Chen RL; Ogunshola OO; Yeoh KK; Jani A; Papadakis M; Nagel S; Schofield CJ; Buchan AM
J Neurochem; 2014 Oct; 131(2):177-89. PubMed ID: 24974727
[TBL] [Abstract][Full Text] [Related]
19. Randomized placebo-controlled dose-ranging and pharmacodynamics study of roxadustat (FG-4592) to treat anemia in nondialysis-dependent chronic kidney disease (NDD-CKD) patients.
Besarab A; Provenzano R; Hertel J; Zabaneh R; Klaus SJ; Lee T; Leong R; Hemmerich S; Yu KH; Neff TB
Nephrol Dial Transplant; 2015 Oct; 30(10):1665-73. PubMed ID: 26238121
[TBL] [Abstract][Full Text] [Related]
20. Salidroside and FG-4592 ameliorate high glucose-induced glomerular endothelial cells injury via HIF upregulation.
Xie RY; Fang XL; Zheng XB; Lv WZ; Li YJ; Ibrahim Rage H; He QL; Zhu WP; Cui TX
Biomed Pharmacother; 2019 Oct; 118():109175. PubMed ID: 31351423
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
